Man with a plan: Emil Kakkis aims to lure big-market drugs toward rare diseases
Emil Kakkis is making another run at rare diseases.
The president and CEO of Ultragenyx Pharmaceutical Inc. and former chief medical officer at BioMarin Pharmaceutical Inc. is laying out a new strategy Tuesday to get more drugs into children with rare diseases. Under the banner of the EveryLife Foundation for Rare Diseases, which Kakkis founded and has largely bankrolled, he is proposing that companies with already-approved, big-market drugs be rewarded with a two-month extension of that drug’s patent life if it wins a new Food and Drug Administration-approved label in an orphan disease.
Read the full story here.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.